REBECCA COOKSLEY: Open Payments
NPI 1700400512 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,065 in 58 payments from 16 companies in 2025. Trend: 2023 $615 · 2024 $680 · 2025 $1,065
Food & beverage: $1,065
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $374 |
| Otsuka America Pharmaceutical, Inc. | 15 | $244 |
| Novo Nordisk Inc | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| Medtronic, Inc. | 1 | $42 |
| PFIZER INC. | 2 | $39 |
| Novartis Pharmaceuticals Corporation | 1 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| SANOFI PASTEUR INC. | 2 | $33 |
| Seqirus USA Inc | 1 | $22 |
Products named: REXULTI, VRAYLAR, Ozempic, QULIPTA, CAPLYTA, SYMPLICITY G3, NURTEC ODT, Veozah.
Industry payments across NE — which companies pay providers there.
